DOI:
10.1055/s-00023610
Drug Research
LinksClose Window
References
Davies A.
Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin’s lymphoma: An overview of pharmacokinetics and clinical trial outcomes.
Exp Rev Hematol 2015;
8: 581-593
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.